Cancer drugs approved quickly but not to patient’s benefit, researcher says

Highly priced cancer drugs get rushed approvals despite poor trial methodology and little effect on the longevity of patients, cautions one expert, who adds that drug reviewers don’t look at the long term survival of patients who take them.